Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
5579-81-7
Molecular formula
C4H9AlN4O5
Molecular weight
220.12 g/mol
Drug class
Gastroprotective aluminium complexmucosal protective and anti-ulcer agent
Mechanism of action
A complex of dihydroxyaluminium and allantoin. Aluminium hydroxide-related components provide local mucosal coating and protection, while the allantoin moiety has reported anti-inflammatory and tissue-protective effects. The precise clinical mechanism is not fully established.
Indications / reported uses
Historically and in some countries used for symptomatic treatment of gastritis, gastric irritation and peptic ulcer-related symptoms; current indications and availability are product- and jurisdiction-specific.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Aldioxa Environmental Risk Assessment (ERA) (the Aldioxa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.